(Q36448312)

14 August 2017

title

Contrast-induced nephropathy: pharmacological prophylaxis (English)

1 reference

contrast-induced nephropathy

14 August 2017

main subject

1 reference

Briguori C

1

1 reference

14 August 2017

Marenzi G

series ordinal

2

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Kidney International. Supplement

14 August 2017

published in

1 reference

14 August 2017

issue

100

1 reference

14 August 2017

page(s)

S30-8

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000372

14 August 2017

exact match

0 references

cites work

N-acetylcysteine ameliorates renal microcirculation: studies in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine and contrast agent-associated nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effect of N-acetylcysteine on serum creatinine level

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Acetylcysteine for prevention of contrast nephropathy: meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Renal side effect of nifedipine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effects of Misoprostol on Contrast-Induced Renal Dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Nephrotoxicity from contrast media: attenuation with theophylline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The role of theophylline in contrast-induced nephropathy: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Contrast-induced nephrotoxicity: the effects of vasodilator therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Use of dopamine in prevention of contrast induced acute renal failure--a randomised study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000372

7 January 2021

Dimensions Publication ID

Identifiers

DOI

10.1038/SJ.KI.5000372

0 references

1023613140

0 references

1 reference